TIDMNARA 
 
12 April 2022 
 
                            PanGenomic Health Inc. 
 
                        ("PanGenomic" or the "Company") 
 
            Admission to Trading on AQSE and First Day of Dealings 
 
PanGenomic Health Inc. ("PanGenomic" or the "Company") (AQSE:NARA) (CSE:NARA), 
a precision health company that has developed a self-care digital platform to 
deliver personalised, evidence-based information about natural treatments to 
support mental health, is pleased to announce that it has completed its 
admission to the Access segment of the Aquis Stock Exchange ("AQSE") and 
trading will commence at 8:00 a.m., 12 April GMT ("Admission") under the ticker 
"NARA" and with its existing ISIN CA69842E2050. The Company's shares will also 
continue to trade on the Canadian Securities Exchange ("CSE"). 
 
The Company has three digital health platforms: 
 
i)             Nara App - a mental health mobile app which provides consumers 
with a knowledge base tailored to an individual's unique user profile, 
developed by tracking a user's treatment regimen and their specific genomic, 
proteomics and microbiomic data. 
 
ii)            Mindleap.com -  an app and telehealth platform for holistic 
mental wellness which grants users access to great audio content and blogs, a 
mental health tracker, and access to professional services for mental 
well-being. Mindleap.com was acquired in November 2022 when the Company 
purchased the entire issued share capital for Mindleap Health Inc from Mydecine 
Innovations Group Inc.; and 
 
iii)           Mujn Diagnostics - a digital therapeutics clinic platform which 
provides health practitioners with access to a consumer's Nara App data in 
order to assist them to optimize the identification of appropriate natural 
remedies and monitor a patient's prognosis during treatment. 
 
Robert Nygren, Executive Chair of PanGenomic, commented: 
 
"The AQSE Growth Market listing presents PanGenomic Health with a tremendous 
opportunity to reach UK-based investors interested in growth companies in the 
digital health sector. Information about effective natural remedy solutions for 
mental health conditions is in great demand, and our subscription-based digital 
health platform has been designed to help individuals find trusted information 
in a user-friendly manner." 
 
The Company will have a dual listing with its common shares fully fungible 
through a CREST Depositary Interest ("CDI").  The CDIs will carry the same ISIN 
as the Common Shares listed in Canada on the CSE. The issued share capital of 
PanGenomic comprises 99,128,169 Ordinary shares. Novum Securities will act as 
the AQSE Corporate Advisor to PanGenomic going forward. 
 
Sector Classification: 
 
The Company will be classified as a Healthcare company on Access Segment of the 
Aquis Stock Exchange. 
 
This announcement, together with any documents incorporated by reference, shall 
be deemed to constitute an admission document for the purposes of the AQSE 
Growth Market Rules for Issuers - Access. It has not been approved or reviewed 
by the Aquis Stock Exchange or the Financial Conduct Authority. 
 
The Directors are of the opinion, having made due and careful enquiry, that the 
working capital available to the Company is sufficient for a period of at least 
twelve months following admission. 
 
The Directors of PanGenomic take responsibility for this announcement. 
 
This announcement contains inside information for the purposes of Article 7 of 
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law 
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed 
in accordance with the Company's obligations under Article 17 of MAR. 
 
 
For further information, please contact: 
 
PanGenomic Health Inc. 
Jerry Lai 
Investor Relations, Canada 
+1 778 743 4642 
ir@pangenomic.com 
Maryam Marissen 
President & CEO 
+1 778 743 4642 
info@pangenomic.com 
Website: https://www.pangenomic.com/ 
 
Novum Securities Limited, AQSE corporate Advisor 
David Coffman / George Duxberry 
Tel: +44 (0)207 399 9400 
 
Yellow Jersey PR 
Charles Goodwin / Shiv Thambirajah / Soraya Jackson 
Investor Relations, UK 
Tel: +44 (0)20 3004 9512 
 
 
About PanGenomic Health 
 
PanGenomic Health is a precision health company that has developed a self-care 
digital platform to deliver personalized, evidence-based information about 
natural treatments. The Company's initial focus is to support mental health. 
Registered as a British Columbia benefit company, PanGenomic Health's mission 
is to promote and improve the health and wellness of people and society by 
providing a technology platform that identifies plant-based solutions tailored 
to the health profile of each individual. 
 
Directors 
 
Vincent Lum 
 
Mr. Lum has almost 20 years of experience in life science and medical device 
company operations, along with investment and venture capital experience. 
Vincent has served as CEO of Metaara Medical Diagnostics, CFO of Vidigami, CFO 
of Hemex Health and CFO of CardioDigital (acquired by Medtronic). Vincent has 
also served as VP and Venture Partner of MDS Capital and VP and Venture 
 
partner of RBC Venture Capital and Manager of Investments at Advanced Systems 
Institute. Vincent holds an MSc in Microbiology and Immunology and an MBA from 
The University of British Columbia. 
 
Robert Nygren 
 
Mr. Nygren co-founded the psychedelics biotechnology company Havn Life Sciences 
(CSE:HAVN) and is a founding director of Psy Integrated Health Corp, which owns 
the Empower Health integrative health clinic in Vancouver. Robert also 
co-founded the ETC3 Tech Centre in the South Research Campus of The University 
of British Columbia, which provides facilities, funding and advisory services 
for life science, agritech, cleantech and fintech companies. Previously, Robert 
was CEO of Epic Data, a publicly-traded 
 
software company, and CEO of Fincentric, a core-banking system sold to Open 
Solutions (now Fiserv). Robert holds an LLB from Western University. 
 
Peter Green 
 
Mr. Green has leadership experience in both large corporations and small 
businesses in the cloud technologies, AI, mobile and telecommunications 
sectors. He has served as president of business solutions at Telus with 
responsibility for its Telus Health division. Peter previously served as CEO 
and a director of Mobilum Technologies Inc. (CSE: MBLM). Mr. Green is also a 
director of Fobi AI Inc. (TSX.V: FOBI). Mr. Green received an Ordinary National 
Diploma, Business Studies from Nelson and Colne College. 
 
Jonathan Lutz 
 
Mr. Lutz has experience in the video game industry, having served in various 
executive management positions at Electronic Arts (EA) since 1998. He recently 
had responsibility for Corporate Strategy, CTO Finance and Strategy, Operations 
& Finance leadership for EA's Strategic Growth Division. Jonathan previously 
served as CFO of EA Canada. Mr. Lutz received an MA from Christ's College, 
Cambridge University and is an Associate of the Chartered Institute of 
Management Accountants. 
 
Senior Management 
 
Maryam Marissen - Chief Executive officer 
 
Ms. Marissen has over two decades of experience in consumer product marketing, 
private clinic services and public advocacy.  She helped establish one of the 
first online personal care and wellness e-commerce stores in North America. As 
Managing Director of a Canadian government relations and public affairs agency, 
she oversaw advocacy campaigns for healthcare, education, and public policy. 
She has also been involved in psychedelic therapy research, consulting with 
academic, industry, and regulatory stakeholders to develop clinical pathways to 
patient care. 
 
Kaidong Zhang - Chief Scientific Officer 
 
Mr. Zhang has over 15 years of life science experience in academia and 
industry. Recent R&D projects include clinical diagnosis development, 
integrative medicine-based chronic disease management, nutraceutical product 
development, and non-invasive diagnostic/therapeutic devices to manage chronic 
prostate disease and non-alcoholic fatty liver diseases. Kaidong received a 
postdoctoral training in protein engineering from the University of Rochester 
and holds a PhD in Medicinal Chemistry and Organic Chemistry from the 
University of Manitoba. 
 
Colin Quon - Chief Technology Officer 
 
Mr. Quon has managed complex technology projects and teams for nearly 30 years 
in Canada. As founder of Excelar, he has overseen the development of health 
data platforms for leading health authorities and academic institutions in 
British Columbia. Colin also has significant experience developing 
telecommunications platforms, during his product development and executive 
roles at Nortel, Telos, EQO Communications, Global Relay and most recently as 
founder of Chatnels Software. Colin holds an MBA from The University of British 
Columbia and a BASc. in Electrical Engineering from Simon Fraser University. 
 
Tammy Gillis - Chief Financial Officer, Secretary and Treasurer 
 
Ms. Gillis has over 20 years' experience in the public markets bringing a 
background in finance, reporting and regulatory requirements of manufacturing, 
technology, and junior exploration industries. She obtained her CPA and CMA in 
2008. Ms. Gillis previously served as CFO of New World Resource Corp., Northern 
Lion Gold Corp, Valorem Resources Inc., Nano One Materials Corp. and Cava 
Healthcare Inc. 
 
This news release includes certain statements that may be deemed 
"forward-looking statements", including statements respecting the services to 
be provided by PanGenomic and the consideration to be paid to PanGenomic. The 
use of any of the words "anticipate", "continue", "estimate", "expect", "may", 
"will", "would", "project", "should", "believe" and similar expressions are 
intended to identify forward looking statements. Although PanGenomic believes 
that the expectations and assumptions on which the forward-looking statements 
are based are reasonable, undue reliance should not be placed on the 
forward-looking statements because PanGenomic can give no assurance that they 

will prove to be correct. Since forward-looking statements address future 
events and conditions, by their very nature they involve inherent risks and 
uncertainties. These statements speak only as of the date of this News Release. 
Actual results could differ materially from those currently anticipated due to 
a number of factors and risks including various risk factors discussed in 
PanGenomic's disclosure documents which can be found under PanGenomic's profile 
on www.sedar.com. 
 
 
 
END 
 
 

(END) Dow Jones Newswires

April 12, 2023 02:00 ET (06:00 GMT)